News Column

Studies from Leiden University Reveal New Findings on Hemic and Immune Systems

February 6, 2014

By a News Reporter-Staff News Editor at Gene Therapy Weekly -- A new study on Immunology is now available. According to news reporting originating in Leiden, Netherlands, by NewsRx journalists, research stated, "Severe mycobacterial disease is mostly confined to patients who are immunocompromized either by acquired or inherited causes. One such genetic disorder is Mendelian Susceptibility to Mycobacterial Disease (MSMD), a hot topic within the field of primary immunodeficiency."

The news reporters obtained a quote from the research from Leiden University, "This single gene disorder is characterized by isolated infection with mycobacteria or Salmonella due to a defect in the type-1 cytokine response. In the last two decades, ten genes have been labeled as causing MSMD when they harbor germline mutations, namely IL12B, IL12RB1, IFNGR1, IFNGR2, STAT1, IKBKG, CYBB, TYK2, IRF8 and ISG15. The mutations lead to either insufficient production of IFN-gamma, or to an insufficient response to the cytokine. Current treatment options include recombinant IFN-g and hematologic stem cell transplantation (HSCT). In the future, gene therapy, antisense-mediated exon skipping and chemical intervention in glycosylation problems may become successful alternatives."

According to the news reporters, the research concluded: "Furthermore, it is likely that many new candidate genes and pathways crucial for mycobacterial immunity will be identified."

For more information on this research see: Nontuberculous mycobacterial infections in children with inborn errors of the immune system. Journal of Infection, 2014;68():S134-S150. Journal of Infection can be contacted at: W B Saunders Co Ltd, 32 Jamestown Rd, London NW1 7BY, England. (Elsevier -; Journal of Infection -

Our news correspondents report that additional information may be obtained by contacting M.H. Haverkamp, Leiden University, Medical Center, Dept. of Infect Dis, NL-2333 ZA Leiden, Netherlands. Additional authors for this research include E. van de Vosse and J.T. van Dissel (see also Immunology).

Keywords for this news article include: Biotechnology, Leiden, Europe, Immunology, Pediatrics, Netherlands, Gene Therapy, Bioengineering, Hemic and Immune Systems

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Gene Therapy Weekly

Story Tools